Estimating the Cost-Effectiveness of Tumor Treating Fields (TTFields) Therapy with an Immune Checkpoint Inhibitor or Docetaxel in Metastatic Non-Small Cell Lung Cancer
The addition of TTFields therapy to an ICI or docetaxel in metastatic NSCLC demonstrates comparable cost-effectiveness to other approved treatments. ICERs fall within the accepted range for US cost-effectiveness thresholds, supporting their use in clinical practice. TTFields therapy extended mean lifetime survival, offering a clinically meaningful and economically justifiable option for patients progressing after platinum-based chemotherapy.
Authors
- Christian Kruhl
- Wesley Furnback (ORCID: https://orcid.org/0000-0001-5532-9688)
- Bruce Wang (ORCID: https://orcid.org/0000-0003-3486-5494)
- Rupesh Kotecha (ORCID: https://orcid.org/0000-0001-6927-0402)
- Cloe Ying Chee Koh (ORCID: https://orcid.org/0000-0003-0800-7445)
- Elizabeth Wu (ORCID: https://orcid.org/0000-0002-6492-3336)
- Juan Guzman (ORCID: https://orcid.org/0000-0003-2172-3083)
Institutions
- Baptist Hospital of Miami (US)
- Baptist Health South Florida (US)
- Novo Nordisk (Switzerland) (CH)
- Novocure (United States) (US)
Publication Details
- Journal
- ClinicoEconomics and Outcomes Research
- Published
- 2025-02-01
- DOI
- https://doi.org/10.2147/ceor.s501532
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Novocure